This study provides preliminary evidence that persons with neurological weakness due to SCI can learn to walk with little or no assistance and light to somewhat hard perceived exertion using a powered exoskeleton. Persons with different severities of injury, including those with motor complete C7 tetraplegia and motor incomplete C4 tetraplegia, may be able to learn to use this device.

Objective To provide a clinically useful means of interpreting change for individual patients on the Neurological Quality of Life (Neuro-QoL) adult short forms (SFs) by applying a Classical Test Theory concept for interpreting individual change. Design Secondary analysis of existing data. Setting Community. Participants Persons with neurological conditions including stroke, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease residing in community settings. Interventions Not applicable. Main Outcome Measures Neuro-QOL SFs for Applied Cognition-General Concerns, Applied Cognition-Executive Function, Applied Cognition-Combined, Ability to Participate in Social Roles and Activities, Satisfaction with Social Roles and Activities, Positive Affect and Well-Being, Depression, Stigma, Upper Extremity Function (Fine Motor, Activities of Daily Living), Lower Extremity Function (Mobility), Anxiety, Sleep Disturbance, Fatigue, and Emotional and Behavioral Dyscontrol. Methods We estimated conditional minimal detectable change (cMDC) indices from the pooled standard errors (SEs) adjusted for a 95% confidence interval (CI) using the average of the SEs for any given pair of scores multiplied by the z-score, or [(SEScore1 +SEScore2)/2 · 1.96]. Results The cMDC indices are generally smallest in the mid-range of all scales, ranging from 3.6 to 11.2 T-score points, and higher on the outer quartiles ranging from 3.7 to 21.6 T-score points. The lowest mid-range cMDCs were for Satisfaction with Social Roles and Activities (3.6–4.7 T-score points) and the largest was for Sleep Disturbance (9.4–11.2 T-score points). Conclusions Change indices can help clinicians and investigators identify differences for individual patients or subjects that are large enough to motivate treatment change. cMDCs can reduce misclassification of magnitudes of change that are near the margins of error across the range of the Neuro-QoL SFs.

No abstract

No abstract